z-logo
Premium
The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions
Author(s) -
Atkin Catherine,
ReddyKolanu Vinay,
Drayson Mark T.,
Sapey Elizabeth,
Richter Alex G.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16487
Subject(s) - monoclonal gammopathy of undetermined significance , medicine , multiple myeloma , serum protein electrophoresis , population , kidney disease , pediatrics , monoclonal , immunology , antibody , monoclonal antibody , environmental health
Summary Monoclonal gammopathy of undetermined significance (MGUS) affects 3·2% of adults aged >50 years. MGUS carries a life‐long risk of progression to multiple myeloma and causes complications including infection and renal impairment; common causes of hospital admission. This study aimed to assess MGUS prevalence in emergency medical hospital admissions. Patients were recruited from unselected emergency medical admissions in a hospital in the United Kingdom. Serum protein electrophoresis was performed, with immunofixation of abnormal results. Reason for admission and routine test results were recorded. After education about MGUS and myeloma, patients chose whether they wished to be informed of new diagnoses. A total of 660 patients were tested and 35 had a paraprotein suggestive of MGUS. The overall rate of MGUS was 5·3%. MGUS prevalence in those aged >50 years was 6·94%, higher than the previously published rate of 3·2% ( P  < 0·0005). There were higher rates in those with chronic kidney disease (13·75% vs. 4·14%, P  = 0·002), heart failure (14% vs. 4·59%, P  = 0·012), anaemia (8·96% vs. 3·41%, P  = 0·003) or leucocytosis (9·33% vs. 3·04%, P  = 0·002). In all, 96% of patients wished to be informed of their screening results. The prevalence of MGUS in emergency hospital admissions is higher than expected based on previous population‐based rates. This may suggest a selected population for screening.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here